
Please try another search
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
Christopher Leo Ntoumenopoulos | 42 | 2024 | Executive Director |
Robin L. Carhart-Harris | - | 2021 | Chairman of Scientific Advisory Board |
Joel Castellanos | - | 2021 | Member of Scientific Advisory Board |
Daniel Tillett | - | 2024 | Non-Executive Director |
David Castle | - | 2024 | Member of Scientific Advisory Board |
Herwig Janssen | - | 2025 | Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review